# Cancer Center Support Grant P30

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2020 · $89,478

## Abstract

PROJECT SUMMARY/ABSTRACT
The UC Davis Comprehensive Cancer Center (UCDCCC), a consortium with Lawrence Livermore National
Laboratories (LLNL), is a matrix organization under the aegis of the UC Davis Health System and University of
California, Davis. Two hundred and four members are organized into six programs, supported by eight shared
resources, and led by Senior Leadership in order to use transdisciplinary, translational, and transformative
research to address the following problems: With a rapidly aging population, 40 million Americans over the age
of 65 are alive today and 390,000 will die from cancer this year. In 15 years, approximately, 74 million
Americans of this age will be alive and cancer mortality will be ~730,000/year. The present methods by which
new cancer therapies have been developed have met with a disappointing failure rate; therefore, improved
translational methods are needed. So too are integrated programs that combine physical sciences, biomedical
technology, and functional imaging to develop new therapies and delivery modalities as well as methods for
functional evaluation and enhanced detection to determine, in a non-toxic fashion, if therapies will work.
Two main foci are used to address these problems:
 1) Reducing disparities in the cancer burden
 2) Tackling advanced cancer by adapting molecularly targeted therapy through our patient derived
 xenograft program (PDX) and canine patients to truly develop personalized medicine.
Each of these uses a multi-disciplinary approach, combining expertise from across programs (Molecular
Oncology, Comparative Oncology, Cancer Therapeutics, Population Sciences and Health Disparities, Prostate
Urothelial Cancer, and Biomedical Technology), leveraging the UC Davis expertise (e.g., School of Medicine,
School of Veterinary Medicine, College of Biological Sciences, Department of Biomedical Technology), and
with external partners (the Jackson Laboratory, Lawrence Livermore National Laboratory, Foundation
Medicine). Seven Innovation Groups enhance collaborative interactions and proposals with focus on
translating basic and technological findings into grants and investigator-initiated trials (IITs). Beyond that, the
UCDCCC’s robust clinical trials program enables these discoveries to be translated into patient benefits. The
portfolio consist of NCI awards to fund Phase I, II, and III trials, COG and NCI Comparative Oncology Trials
Consortium trials, and a strong portfolio of IITs. These are implemented by a cadre of clinical scientists (11 of
whom were recruited in the past funding period) who function as the interface of translational and clinical
research. The catchment area (13 counties surrounding Sacramento county) is benefited through, among other
activities, a city-wide early phase clinical trials program and the UCDCCC Cancer Care Network, through
which the resources and expertise of a comprehensive cancer center are brought to disadvantaged and rural
areas while keeping patients ...

## Key facts

- **NIH application ID:** 10063282
- **Project number:** 3P30CA093373-18S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** PRIMO N. LARA
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $89,478
- **Award type:** 3
- **Project period:** 2002-07-01 → 2021-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10063282

## Citation

> US National Institutes of Health, RePORTER application 10063282, Cancer Center Support Grant P30 (3P30CA093373-18S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10063282. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*